Cholesterol

The results highlight hemoglobin A1c/high-density lipoprotein cholesterol as a potential clinical marker for long-term stroke risk.

High-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B did not have significant correlations with chronic obstructive pulmonary disease.

Challenges include therapy gaps, nonadherence, and fragmented care.

This case report depicts a probable infusion reaction in a 61-year-old woman prescribed evinacumab for the treatment of familial hypercholesterolemia.

Regardless of confounding factors, the ratio of high-sensitivity C-reactive protein to high-density lipoprotein cholesterol predicts the all-cause long-term mortality.

Dyslipidemia is a condition in which there are abnormal levels of lipids in the blood stream, including high levels of low-density lipoprotein cholesterol, low levels of high-density lipoprotein cholesterol, and/or high levels of triglycerides.

Patients with acute coronary syndrome who were in the high quartile were at significantly higher risk for major adverse cardiovascular events (MACE).

Muvalaplin is an oral, small molecule inhibitor that can reduce lipoprotein(a).

High levels of the Oscillibacter genus of bacteria were associated with reduced cholesterol.

Lerodalcibep is a third-generation PCSK9 inhibitor that demonstrated success in reducing low density lipoprotein cholesterol (LDL-C).

Results of the study showed an inverse relationship between BMI and LDL cholesterol changes for those who adopt a low-carbohydrate diet.

Muvalaplin inhibits the formation of Lp(a) by blocking the initial interaction between apolipoprotein(a) and apo(b).

Lipoprotein(a) is a known risk factor for atherosclerotic cardiovascular disease.

Familial chylomicronemia syndrome (FCS) currently has no FDA-approved treatment and is associated with an increased risk of acute pancreatitis.

Twice-yearly dosing could significantly improve adherence rates.

Improving collaboration and communication between all members of the health care team is one way to address these challenges.

High fluctuations (in the top 25%) in total cholesterol were associated with a 60% increase in dementia and a 23% increase in cognitive decline.

Lerodalcibep is a novel, third-generation, anti-PCSK9 therapy small binding protein.

Bisphenol A (BPA) is a chemical compound that is linked to various adverse health effects.

New recommendations from the American Stroke Association (ASA) emphasize the importance of healthy lifestyle habits and addressing health equity to reduce stroke risk.

The researchers observe that the combination treatment results in higher serum levels compared with ezetimibe alone.

Zodasiran is an RNA interference therapy targeting the ANGPTL3 loss-of-function mutation.

High cholesterol levels are known risk factors for atherosclerotic cardiovascular disease.

Cholesin, a hormone found in the gut, may enhance the cholesterol-lowering capabilities of statins.

Exposure to high cholesterol levels is a significant risk factor for atherosclerosis cardiovascular disease.

FCS is a severe, rare genetic disease in which patients have extremely high triglyceride levels, typically above 880 mg/dL.

Alirocumab (Praluent; Regeneron), is a PCSK9 inhibitor indicated for the treatment of adults with heterozygous familiar hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease.

Pharmacists can enhance ASCVD management by supporting patient adherence through the administration and monitoring of inclisiran.

Pharmacists play an essential role in ensuring the medication is dispensed to patients with high atherosclerotic cardiovascular disease risk.

Pharmacists can play a crucial role in educating patients on the proper storage and administration of evolocumab.